Lexaria Bioscience Corp. reported a net loss of USD 11.9 million for the full year ended August 31, 2025. This compares to a net loss of USD 5.8 million in the previous year. IP Licensing revenue for the period was USD 0.7 million, representing an increase of 52 percent. B2B revenue totaled USD 9,923. The company stated that its existing cash and anticipated inflows from license agreements are not expected to meet operational requirements for the next twelve months, raising substantial doubt about its ability to continue as a going concern. Since entering the bioscience sector, Lexaria has accumulated net losses of USD 63.5 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-25-002225), on November 28, 2025, and is solely responsible for the information contained therein.